Nano Pharmaceuticals Development

Our projects and research in nano based drugs and nanomedicine have demonstrated remarkable success in revolutionizing healthcare and improving the quality of life for people around the world. Regardless of their background, religion, or financial standing, we are dedicated to ensuring that all individuals have access to the basic daily services and products they need to maintain a high quality of life.

The department of human health sustainability at the DUSSRC is dedicated to conducting cutting-edge research and projects in various areas related to vaccine and drug delivery, drug preparation, and development.

Adhering to the stringent standards of ISO 9001:2015 for quality control analysis, our team ensures that all processes are carried out with precision and accuracy.

Our research endeavors encompass a wide range of topics, with a particular focus on vaccines and the study of liposomes. We delve deep into the development of lipid nanoparticles (LNPs) for various applications, including mRNA-based COVID-19 vaccines. By employing advanced nanoscale detectors and Size Exclusion Chromatography (SEC) technologies, we meticulously analyze the stability of LNPs and optimize their isolation and purification processes using centrifugation and filtration techniques. While LNPs have gained prominence in the realm of vaccine development, their versatility extends beyond this realm. These lipid-based nanoparticles serve as efficient carriers for delivering therapeutic molecules such as RNA, mRNA, and siRNA, playing a pivotal role in gene editing and targeted drug delivery.

Our utilization of qEV columns has proven instrumental in isolating and purifying lipid-based nanoparticles. In a recent study focusing on liposomes containing anti-inflammatory steroids, the qEV columns facilitated the evaluation of drug entrapment capacity and removal of free dye, thereby enhancing the efficiency of drug-loaded liposome isolation based on size.Moreover, our research extends to the purification of antibody-conjugated LNPs, which are harnessed for delivering therapeutic RNA to hematopoietic stem and progenitor cells (HSPCs) in vivo. By leveraging qEV Nanoparticle lipids isolation (LNP) techniques, we have made significant strides in advancing drug delivery systems and vaccine development.

As we look towards the future, our focus remains on the development of Nanobiotics and ensuring the stability of their chemical and physical properties. Additionally, we are actively exploring innovative extraction resources to pave the way for greener and more sustainable drug development practices.